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Genetic mutations provide mechanisms that allow viruses to adapt to a new host and avoid its immune 
responses. Currently, various variants of SARS-Cov-2 have been reported, based on evaluations of their genetic 
mutations, which have been named by the World Health Organization, among others, as variants of concern (1).
Within these variants, the so-called "Delta" variant (Lineage B.1.617.2), has two mutations (E484Q and L452R) 
that allow it to be more bound to ACE2 and to evade the immune system. Initially, variant B.1.617.2 was 
considered as transmissible as variant B.1.1.7, however, it is suggested that this variant may be more than 60% 
more transmissible than variant Alpha (2).
The resolution of SARS-CoV-2 and COVID-19 infection may depend on the responses of CD4 + and CD8 + T 
cells, which also play a role in modulating the severity of the disease (3, 4).
Given this, in convalescent individuals, T-cell immunity is not restricted to spike-derived epitopes and, therefore, 
it would be reasonable to assume that it would remain largely intact for the new variants (5).
However, in recipients of available vaccines, where protein S is the target immunogen, T cell immunity is limited 
to spike epitopes (6).
Therefore, the goal of genetic studies is to determine whether new variant mutations in these epitopes affect T-
cell responses in a similar way to the escape of neutralizing antibodies.
The concern that these mutations imply is the emergence of a third wave in the COVID-19 pandemic, associated 
with this new variant. As of July 2021, approximately 4 cases of this variant have been identified in the cities of 
Lima and Arequipa, so preventive measures have already been taken to detect and surround suspected cases 
and contacts with positive patients.
The impact that this variant may have on the progress of the fight against the pandemic is still unknown, as well 
as the effect between vaccinated patients and those who have yet to immunize.
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